Purpose: With the rising survival rate among children and adolescents with acute lymphoblastic leukemia (ALL), prioritizing patient-centered care to address the long-term effects of chemotherapy through tailored rehabilitation interventions is essential for optimizing their quality of life. The purpose of this study was to investigate the impact of an 8-week intervention using adaptive variable-resistance training (Adaptive-VRT) on chemotherapy-induced sarcopenia, fatigue, and functional restrictions in pediatric survivors of ALL.
Methods: A prospective randomized controlled trial included a total of 62 survivors of ALL, aged 12-18 years, and completed maintenance chemotherapy. Participants were randomized into two groups: the Adaptive-VRT group (n = 31), assigned the Adaptive-VRT intervention, and the control group (n = 31), which adhered to the standard exercise protocol. Baseline and post-intervention measurements were undertaken to analyze sarcopenia-related variables (i.e., muscle thickness and muscle strength), fatigue, and functional performance.
Results: The Adaptive-VRT group exhibited more favorable changes in muscle thickness [thigh thickness (P < .001; η = 0.32); rectus femoris (P < .001; η = 0.21); vastus intermedius (P = .002; η = 0.15)], and peak concentric torque of quadriceps [at speed of 90°/s (P = .005; η = 0.13), 120°/s (P = .021; η = 0.10), or 180°/s (P = .008; η = 0.11)] in comparison with the control group. Additionally, the Adaptive-VRT group reported lower fatigue levels (P = .031; η = 0.08) and demonstrated better functional performance [6-min walk test (P < .001; η = 0.25), 4 × 10-m shuttle running test (P < .001; η = 0.24), as well as timed up and down stairs (P < .0006; η = 0.18)].
Conclusion: The findings suggest that Adaptive-VRT is a promising intervention for ameliorating chemotherapy-induced sarcopenia, fatigue, and functional limitations in pediatric ALL survivors.
Trial Registration: ClinicalTrials.gov Identifier: NCT06338020.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-025-09250-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comorbidities of hypothyroidism.
Curr Med Res Opin
March 2025
Merck Healthcare KGaA, Darmstadt, Germany.
Hypothyroidism is a relatively common condition that may affect as many as 10% of the population worldwide when its overt and subclinical presentations are considered. Important clinical comorbidities are highly prevalent in people with hypothyroidism and diminish quality of life and functional status in a manner that is proportional to the number of comorbidities present and their severity. This article reviews the common comorbidities of hypothyroidism, as reported in the literature.
View Article and Find Full Text PDFAllergen Immunotherapy in Autoimmune Terrain: A Case Study.
Indian J Otolaryngol Head Neck Surg
January 2025
Department of Endocrinology, Joshi Clinic, Mumbai, India.
Allergen immunotherapy (AIT), or specific immunotherapy (SIT), is an effective treatment for inducing immune tolerance to specific allergens. It is widely used for allergic rhinitis, conjunctivitis, asthma, and Hymenoptera venom allergies, with recent applications to food allergies and atopic dermatitis. Despite its benefits, the use of SIT in patients with autoimmune diseases is controversial due to concerns about its potential to induce or exacerbate autoimmune conditions.
View Article and Find Full Text PDFNeural correlates of fatigue after traumatic brain injury.
Brain Commun
February 2025
Division of Neurorehabilitation, Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva 14 1211, Switzerland.
Fatigue is the main cause of disability after traumatic brain injury and has negative impact on social, physical and cognitive functions, participation in daily activities, and ability to work. Since the neural underpinnings are largely unknown, few causal treatments are currently available. This study therefore aimed to investigate the neural correlates of subjective fatigue after traumatic brain injury, controlling for differences in cognitive performance, motor performance and subjective psychological covariates such as depression, anxiety and apathy.
View Article and Find Full Text PDFCombining a 9-month tailored physical exercise program with osimertinib and denosumab in a patient affected by advanced NSCLC with multiple osteolytic bone lesions: A case report.
Heliyon
February 2025
Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Italy.
A 55-year-old female patient affected by an EGFR mutant NSCLC with multiple lytic bone metastases and two prior pathological fractures, undergoing treatment with osimertinib and denosumab, participated in a 9-month physical exercise program. The exercise program was performed twice a week and consisted of aerobic and strength training. Aerobic training was composed of moderate-intensity continuous training for the first 3 months and then high-intensity interval training.
View Article and Find Full Text PDFSphenopalatine Ganglion Block Using the Tx360 Nasal Applicator for Trigeminal Neuralgia: A Prospective Observational Pilot Study.
Cureus
February 2025
1st Department of Anesthesiology and Pain Medicine, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, GRC.
Introduction Trigeminal neuralgia (TN) is a chronic condition characterized by sudden, short episodes of excruciating facial pain affecting one or more branches of the trigeminal nerve (V), which severely impacts patients' quality of life. Despite the availability of various treatment options, some cases experience poor pain control. Sphenopalatine ganglion (SPG) block using the Tx360 nasal applicator has recently been introduced with promising results as a treatment option in such cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!